Breaking News Instant updates and real-time market news.

MRK

Merck

$76.33

1.6 (2.14%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22

Merck provides update on Phase 3 KEYNOTE-062 trial

Merck announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma. In the monotherapy arm of the study, KEYTRUDA met a primary endpoint by demonstrating noninferiority to chemotherapy, the current standard of care, for overall survival in the entire intention-to-treat population of patients whose tumors expressed PD-L1. In the combination arm of KEYNOTE-062, KEYTRUDA plus chemotherapy was not found to be superior for OS or progression-free survival compared with chemotherapy alone. The safety profile of KEYTRUDA was consistent with that previously observed in gastric cancer. Results will be presented during an oral session at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago on June 2, and will be discussed with regulatory authorities.

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 06

    May

  • 18

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

MRK Merck
$76.33

1.6 (2.14%)

03/11/19
WBLR
03/11/19
NO CHANGE
WBLR
Outperform
William Blair sum-of-the-parts analysis yields $19.80 value for Pfenex
The majority of Pfenex (PFNX) investor focus has been placed on lead asset PF708, the therapeutic equivalent product candidate to Forteo, William Blair analyst Andy Hsieh tells investors in a research note, citing his talks with clients. The analyst, however, sees "potential for significant value" from the company's collaboration with Jazz Pharmaceuticals (JAZZ). The deal with Jazz could provide patients with an alternative to Erwinaze/Erwinase, which currently suffers from significant supply constraints, and CRM197, a carrier protein that is incorporated as an adjuvant in several vaccine candidates, including Merck's (MRK) pneumococcal vaccine, V114, Hsieh writes. Based on these royalties, the analyst conducted a sum-of-the-parts analysis for Pfenex based on discounted cash flow, and the resulting net present value yielded a value of $19.80 per share. The stock closed Monday at $4.26. The analyst believes the company's "value-creating" catalysts this year, including milestone payment from Jazz for the successful tech transfer of PF743 and PF745 and the approval of PF708, coupled with his valuation analysis, affirm his bullish thesis. Hsieh believes Pfenex shares offer one of the best risk/reward symmetries in small-cap biotech and reiterates an Outperform rating on the name.
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
04/24/19
UBSW
04/24/19
NO CHANGE
Target $102
UBSW
Neutral
Procter & Gamble price target raised to $102 from $95 at UBS
UBS analyst Steven Strycula raised his price target on Procter & Gamble (PG) to $102, saying that yesterday's sell-off on investor concerns about the company's ability to boost margin "overlooks" the "upcoming inflection". The analyst keeps his Neutral rating, but notes that the Q3 margin pressure was "transitory" as it was impacted by adverse FX, commodities, higher bonus, and Merck (MRK) integration headwinds.

TODAY'S FREE FLY STORIES

AXSM

Axsome Therapeutics

$24.17

-1.11 (-4.39%)

07:40
06/24/19
06/24
07:40
06/24/19
07:40
Hot Stocks
Axsome Therapeutics initiates GEMINI Phase 3 trial of AXS-05 »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$50.62

-0.7 (-1.36%)

, APC

Anadarko

$70.37

-0.1 (-0.14%)

07:40
06/24/19
06/24
07:40
06/24/19
07:40
Downgrade
Occidental Petroleum, Anadarko rating change  »

Occidental Petroleum…

OXY

Occidental Petroleum

$50.62

-0.7 (-1.36%)

APC

Anadarko

$70.37

-0.1 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

BAESY

BAE Systems

$0.00

(0.00%)

07:39
06/24/19
06/24
07:39
06/24/19
07:39
Hot Stocks
BAE Systems awarded $90M Navy contract for C5ISR systems »

The U.S. Navy has awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLT

Applied Therapeutics

$8.67

-0.83 (-8.74%)

07:39
06/24/19
06/24
07:39
06/24/19
07:39
Hot Stocks
Applied Therapeutics initiates Phase 1/2 sstudy of AT-007 »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NERV

Minerva

$4.23

0.03 (0.71%)

07:39
06/24/19
06/24
07:39
06/24/19
07:39
Conference/Events
Minerva to hold a conference call »

Chairman & CEO, Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CR

Crane

$80.73

-1.715 (-2.08%)

, CIR

Circor

$45.80

-0.19 (-0.41%)

07:38
06/24/19
06/24
07:38
06/24/19
07:38
Hot Stocks
Circor rejects unsolicited tender offer from Crane »

Circor (CIR) announced…

CR

Crane

$80.73

-1.715 (-2.08%)

CIR

Circor

$45.80

-0.19 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

BWAY

Brainsway

$10.09

-0.16 (-1.56%)

07:38
06/24/19
06/24
07:38
06/24/19
07:38
Hot Stocks
Brainsway announces shipment of 100th Deep TMS helmet for treatment of OCD »

BrainsWay announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLNE

Hamilton Lane

$56.76

0.29 (0.51%)

07:36
06/24/19
06/24
07:36
06/24/19
07:36
Hot Stocks
Hamilton Lane closes latest co-investment fund above target »

Hamilton Lane announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

07:35
06/24/19
06/24
07:35
06/24/19
07:35
General news
U.S. equities are modestly higher »

U.S. equities are…

DFRG

Del Frisco's

$6.73

-0.18 (-2.60%)

07:34
06/24/19
06/24
07:34
06/24/19
07:34
Hot Stocks
Del Frisco's to be acquired by L Catterton for approx. $650M »

Del Frisco's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 13

    Nov

DE

Deere

$164.29

1.49 (0.92%)

07:34
06/24/19
06/24
07:34
06/24/19
07:34
Upgrade
Deere rating change  »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 17

    Jul

TRVN

Trevena

$1.01

-0.04 (-3.81%)

07:32
06/24/19
06/24
07:32
06/24/19
07:32
Hot Stocks
Trevena announces publication of APOLLO-2 results in Pain Practice »

Trevena announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

WPC

W.P. Carey

$85.49

-0.51 (-0.59%)

07:32
06/24/19
06/24
07:32
06/24/19
07:32
Hot Stocks
W.P. Carey announces recent investments totaling approximately $53M »

W. P. Carey announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$130.97

0.13 (0.10%)

07:30
06/24/19
06/24
07:30
06/24/19
07:30
Hot Stocks
Allergan receives FDA clearance for CoolTone device »

Allergan announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPX

Tempur Sealy

$74.38

0.95 (1.29%)

, BIG

Big Lots

$28.98

-0.375 (-1.28%)

07:30
06/24/19
06/24
07:30
06/24/19
07:30
Upgrade
Tempur Sealy, Big Lots rating change  »

Tempur Sealy upgraded to…

TPX

Tempur Sealy

$74.38

0.95 (1.29%)

BIG

Big Lots

$28.98

-0.375 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOP

GasLog Partners

$21.49

0.09 (0.42%)

, GLOG

GasLog

$13.36

-0.02 (-0.15%)

07:30
06/24/19
06/24
07:30
06/24/19
07:30
Hot Stocks
GasLog, GasLog Partners agree to eliminate incentive distribution rights »

GasLog (GLOG) and GasLog…

GLOP

GasLog Partners

$21.49

0.09 (0.42%)

GLOG

GasLog

$13.36

-0.02 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:30
06/24/19
06/24
07:30
06/24/19
07:30
General news
Treasury Market Outlook: bonds have caught a bid »

Treasury Market Outlook:…

TRLFF

True Leaf Medicine

$0.00

(0.00%)

, NXTTF

Namaste Technologies

$0.00

(0.00%)

07:27
06/24/19
06/24
07:27
06/24/19
07:27
Hot Stocks
True Leaf Medicine announces supply agreement with Namaste Technologies »

True Leaf Brands (TRLFF)…

TRLFF

True Leaf Medicine

$0.00

(0.00%)

NXTTF

Namaste Technologies

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARLP

Alliance Resource Partners

$16.96

-0.12 (-0.70%)

07:27
06/24/19
06/24
07:27
06/24/19
07:27
Hot Stocks
Alliance Resource Partners to acquire $145M of Permian Basin interests »

Alliance Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNET

RigNet

$8.64

0.22 (2.61%)

, IMASY

Inmarsat

$0.00

(0.00%)

07:25
06/24/19
06/24
07:25
06/24/19
07:25
Hot Stocks
RigNet announces settlement of Inmarsat arbitration »

RigNet (RNET) announced…

RNET

RigNet

$8.64

0.22 (2.61%)

IMASY

Inmarsat

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$76.12

-0.82 (-1.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Upgrade
Fortinet rating change  »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

POST

Post Holdings

$104.28

0.075 (0.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Post Holdings narrows FY19 adjusted EBITDA view $1.2B-$1.22B from $1.2B-$1.24B »

Post Holdings provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMUX

Immunic

$9.71

0.04 (0.41%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Immunic to present unpublished IMU-838 data at GIIDS »

Immunic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

PSTI

Pluristem

$0.57

-0.0142 (-2.43%)

07:21
06/24/19
06/24
07:21
06/24/19
07:21
Hot Stocks
Pluristem appoints Yaky Yanay as sole CEO »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$6.57

-0.19 (-2.81%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Conference/Events
Pfenex management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.